Medical AI Alliance
← Company Index
Pharma & CDMOKOSPI 016580315 approvals107 trials

WHANIN PHARM CO.,LTD

Official website

KOSPI-listed pharma company ranked No.1 in Korea's psychiatric drug market (2024 IMS Data) with neuropsychiatric drugs over 80% of revenue.

As of 2026-10-10, WHANIN PHARM CO.,LTD has 315 Korean MFDS drug approvals, 9 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 1982 and listed on the KOSPI in 1996, Whanin Pharm is a pharmaceutical company specializing in neuropsychiatric drugs. It in-licenses the antidepressant Argotin, the anticonvulsant Zebinix, and the neuropsychiatric drug Clozaril from Servier (France), Bial Portela (Portugal), and Viatris (US) respectively, under 2017-2018 contracts, and distributes them exclusively in Korea. Neuropsychiatric drugs account for over 80% of total revenue, and per 2024 IMS Data the company ranks No.1 in Korea's psychiatric drug market; it is also developing the improved new drugs WIL-1901 (Alzheimer's, market size KRW 316.9bn) and WIP-2401 (depression, KRW 250bn), and the generics WIE-2301/WIE-2302 (essential hypertension, KRW 1.2tn each), WIE-2303 (peptic ulcer, KRW 1,266.6bn), and WIG-2202 (epilepsy, KRW 340bn, approval completed).

Products & technology

  • Argotin (antidepressant)Antidepressant, exclusively distributed in Korea (in-licensed from Servier, France)
  • Zebinix (anticonvulsant)Anticonvulsant, exclusively distributed in Korea (in-licensed from Bial Portela, Portugal)
  • Clozaril (neuropsychiatric drug)Neuropsychiatric drug, exclusively distributed in Korea (in-licensed from Viatris, US)

Regulatory approvals

data.go.kr

315 Korean MFDS drug approvals · 1960–2026

  • MFDS drugPrireptol Cap. 50mg2026-09-15
    Drug · Prescription · Approval202602781
  • MFDS drugWhanIn Atomoxetine Tab. 60mg2026-03-12
    Drug · Prescription · Approval202600750
  • MFDS drugWhanIn Atomoxetine Tab. 80mg2026-02-24
    Drug · Prescription · Approval202600515
  • MFDS drugWhanIn Atomoxetine Tab. 10mg2026-02-10
    Drug · Prescription · Approval202600373
  • MFDS drugWhanIn Atomoxetine Tab. 18mg2026-02-10
    Drug · Prescription · Approval202600374
  • MFDS drugWhanIn Atomoxetine Tab. 25mg2026-02-10
    Drug · Prescription · Approval202600375
  • MFDS drugWhanIn Atomoxetine Tab. 40mg2026-01-07
    Drug · Prescription · Approval202600050
  • MFDS drugTofaciz Tab. 10mg2025-11-24
    Drug · Prescription · Approval202503050
  • MFDS drugBriva Tab. 75mg2025-11-12
    Drug · Prescription · Approval202502931
  • MFDS drugBriva Tab. 100mg2025-09-19
    Drug · Prescription · Approval202502489
  • MFDS drugBriva Tab. 50mg2025-09-19
    Drug · Prescription · Approval202502490
  • MFDS drugBriva Tab. 10mg2025-09-19
    Drug · Prescription · Approval202502491
Show 68 more
  • MFDS drugBriva Tab. 25mg2025-09-19
    Drug · Prescription · Approval202502492
  • MFDS drugOfenib Tab. 100mg2025-05-07
    Drug · Prescription · Approval202501106
  • MFDS drugOfenib Tab. 150mg2025-05-07
    Drug · Prescription · Approval202501107
  • MFDS drug.2025-03-17
    Drug · OTC · Notification202500581
  • MFDS drugWhanIn Memantine Tab. 5mg2025-02-03
    Drug · Prescription · Approval202500214
  • MFDS drugArgotin Tab. 25mg2024-12-26
    Drug · Prescription · Approval202403080
  • MFDS drug환인아질사르탄정80밀리그램(아질사르탄메독소밀칼륨)(수출용)2024-12-24
    Drug · Prescription · Approval202403072
  • MFDS drug환인아질사르탄정40밀리그램(아질사르탄메독소밀칼륨)(수출용)2024-12-24
    Drug · Prescription · Approval202403073
  • MFDS drug환인아질사르탄정20밀리그램(아질사르탄메독소밀칼륨)(수출용)2024-12-24
    Drug · Prescription · Approval202403074
  • MFDS drugDomentia Tab. 10/20mg2024-12-23
    Drug · Prescription · Approval202403047
  • MFDS drugWhanIn Quetapine XR Tab. 50mg2024-09-27
    Drug · Prescription · Approval202402325
  • MFDS drugNiceon tab. 10mg2024-06-19
    Drug · Prescription · Approval202401478
  • MFDS drugWhanIn Memantine Tab. 20mg2024-04-30
    Drug · Prescription · Approval202401044
  • MFDS drugWhanIn Memantine OD Tab. 20mg2024-04-24
    Drug · Prescription · Approval202400958
  • MFDS drugPosarina Tab, 10/5mg2024-04-22
    Drug · Prescription · Approval202400922
  • MFDS drug.2024-03-21
    Drug · Prescription · Approval202400581
  • MFDS drugNiceon tab. 30mg2023-12-14
    Drug · Prescription · Approval202303346
  • MFDS drugVortive Tab. 20mg (Vortioxetine Hydrobromide)2023-05-12
    Drug · Prescription · Approval202301537
  • MFDS drugVortive Tab. 10mg (Vortioxetine Hydrobromide)2023-05-12
    Drug · Prescription · Approval202301538
  • MFDS drugVortive Tab. 5mg (Vortioxetine Hydrobromide)2023-05-12
    Drug · Prescription · Approval202301539
  • MFDS drugPeranel Tab. 10mg2023-03-03
    Drug · Prescription · Approval202300746
  • MFDS drugPeranel Tab. 8mg2023-03-03
    Drug · Prescription · Approval202300747
  • MFDS drugPeranel Tab. 4mg2023-03-03
    Drug · Prescription · Approval202300748
  • MFDS drugDukaforge Tab. 60/5mg2023-01-06
    Drug · Prescription · Approval202300107
  • MFDS drugDukaforge Tab. 60/2.5mg2023-01-06
    Drug · Prescription · Approval202300128
  • MFDS drugDukaforge Tab. 30/2.5mg2023-01-06
    Drug · Prescription · Approval202300135
  • MFDS drugWhanin Sertraline Tab. 25mg (Sertraline Hydrochloride)2022-11-29
    Drug · Prescription · Approval202204286
  • MFDS drugAripizole Tab. 1mg2022-11-09
    Drug · Prescription · Approval202204039
  • MFDS drugAlpram Tab. 0.125mg2022-10-26
    Drug · Prescription · Approval202203919
  • MFDS drugFenacsone Tab.2022-09-22
    Drug · Prescription · Approval202203633
  • MFDS drugWe-ase Tab.2022-05-31
    Drug · OTC · Notification202202291
  • MFDS drugPeranel Tab. 12mg2022-04-19
    Drug · Prescription · Approval202201598
  • MFDS drugPeranel Tab. 6mg2022-04-19
    Drug · Prescription · Approval202201599
  • MFDS drugPeranel Tab. 2mg2022-04-19
    Drug · Prescription · Approval202201600
  • MFDS drugTofaciz Tab. 5mg2022-04-18
    Drug · Prescription · Approval202201584
  • MFDS drugPosarin Tab. 5mg2022-03-15
    Drug · Prescription · Approval202201074
  • MFDS drugDefaxine SR Tab. 25mg2022-01-28
    Drug · Prescription · Approval202200501
  • MFDS drugPosarin Tab. 10mg2022-01-27
    Drug · Prescription · Approval202200440
  • MFDS drugRabemore Tab. 20/500mg2022-01-27
    Drug · Prescription · Approval202200470
  • MFDS drugPosarin Plus Tab. 10/100mg2022-01-12
    Drug · Prescription · Approval202200211
  • MFDS drugRabemore Tab. 10/500mg2021-12-31
    Drug · Prescription · Approval202108209
  • MFDS drugJaroban Tab. 2.5mg2021-12-29
    Drug · Prescription · Approval202108133
  • MFDS drugWhanIn Pitavastatin Tab. 4mg2021-07-01
    Drug · Prescription · Approval202105021
  • MFDS drugWhanIn Pitavastatin Tab. 1mg2021-07-01
    Drug · Prescription · Approval202105022
  • MFDS drugWhanIn Pitavastatin Tab. 2mg2021-07-01
    Drug · Prescription · Approval202105023
  • MFDS drugStadron Inj. 5mg/100mL2021-06-29
    Drug · Prescription · Approval202104919
  • MFDS drugJaroban Tab. 20mg2021-04-22
    Drug · Prescription · Approval202103338
  • MFDS drugJaroban Tab. 15mg2021-04-22
    Drug · Prescription · Approval202103339
  • MFDS drugJaroban Tab. 10mg2021-04-22
    Drug · Prescription · Approval202103340
  • MFDS drugRamipexol ER Tab. 1.5mgRevoked2021-04-20
    Drug · Prescription · Approval202103199
  • MFDS drugRamipexol ER Tab. 0.75mgRevoked2021-04-20
    Drug · Prescription · Approval202103200
  • MFDS drugRamipexol Tab. 1.0mgRevoked2021-03-11
    Drug · Prescription · Approval202102240
  • MFDS drugRamipexol Tab. 0.5mgRevoked2021-03-11
    Drug · Prescription · Approval202102241
  • MFDS drugRamipexol Tab. 0.125mgRevoked2021-03-11
    Drug · Prescription · Approval202102242
  • MFDS drugBemiga SR Tab. 50mg2021-02-18
    Drug · Prescription · Approval202101444
  • MFDS drugCombizet Tab. 10/40mg2021-02-18
    Drug · Prescription · Approval202101513
  • MFDS drugCombizet Tab. 10/20mg2021-02-18
    Drug · Prescription · Approval202101514
  • MFDS drugCombizet Tab. 10/10mg2021-02-18
    Drug · Prescription · Approval202101515
  • MFDS drugMirzentac OD Tab. 7.5mg2020-12-31
    Drug · Prescription · Approval202009438
  • MFDS drugMirzentac OD Tab. 30mg2020-12-24
    Drug · Prescription · Approval202009229
  • MFDS drugMirzentac OD Tab. 15mg2020-12-07
    Drug · Prescription · Approval202008509
  • MFDS drugRamipexol ER Tab. 0.375mgRevoked2020-11-19
    Drug · Prescription · Approval202008000
  • MFDS drugZebinix Tab. 200mg2020-11-10
    Drug · Prescription · Approval202007717
  • MFDS drugZebinix Tab. 800mg2020-11-10
    Drug · Prescription · Approval202007718
  • MFDS drugZebinix Tab. 400mg2020-11-10
    Drug · Prescription · Approval202007719
  • MFDS drugZebinix Tab. 600mg2020-11-10
    Drug · Prescription · Approval202007720
  • MFDS drugCerazin Inj.2020-10-30
    Drug · Prescription · Notification202007461
  • MFDS drugZopita Tab. 1mgRevoked2020-10-14
    Drug · Prescription · Approval202007054

Showing the 80 most recent of 315 records.

Clinical trials

data.go.kr

107 MFDS clinical trial authorisations · 2012–2026 (Bioequivalence 93 · Phase 1 9 · Phase 2 3 · Phase 3 2)

  • BioequivalenceWIG-25012026-09-14

    2 trial sites

  • Phase 1WIF-24022026-09-02

    4 trial sites

  • BioequivalenceWIG-25072026-08-26

    2 trial sites

  • Phase 1WIL-19012026-06-22

    2 trial sites

  • BioequivalenceWIG-25082026-06-02

    2 trial sites

  • BioequivalenceWIG-25082026-06-02

    2 trial sites

  • BioequivalenceWIG-25042026-05-12

    2 trial sites

  • BioequivalenceWIG-25052026-03-13

    2 trial sites

  • BioequivalenceWIG-2503-402026-03-12

    2 trial sites

  • BioequivalenceWIG-2503-102026-03-12

    2 trial sites

  • BioequivalenceWIG-25092026-03-03

    2 trial sites

  • BioequivalenceWIG-25092026-03-03

    2 trial sites

Show 68 more
  • BioequivalenceWIG-25072026-02-06

    2 trial sites

  • Phase 1WIP-24012025-09-09

    2 trial sites

  • BioequivalenceWIG-23012025-07-07

    2 trial sites

  • Phase 1WIG-2401-802025-03-11

    2 trial sites

  • BioequivalenceWIG-22022025-01-09

    2 trial sites

  • Phase 1WIG-24012025-01-07

    2 trial sites

  • Phase 1WIG-24032024-07-02

    2 trial sites

  • BioequivalenceWIG-23042024-04-18

    2 trial sites

  • BioequivalenceWIM-2301B2024-02-19

    2 trial sites

  • BioequivalenceWIM-2301B2024-02-19

    2 trial sites

  • BioequivalenceWIM-2101D2024-02-08

    2 trial sites

  • BioequivalenceWIG-QX152023-06-28

    2 trial sites

  • BioequivalenceWIG-QX152023-03-21

    2 trial sites

  • BioequivalenceWIG-QX152023-03-21

    2 trial sites

  • BioequivalenceWIG-22032022-10-07

    2 trial sites

  • BioequivalenceWIG-2102B2022-03-23

    2 trial sites

  • BioequivalenceWIG-2102B2022-03-17

    2 trial sites

  • BioequivalenceWIG-19032022-02-15

    2 trial sites

  • BioequivalenceWIG-19032022-02-15

    2 trial sites

  • BioequivalenceWIG-21062022-01-24

    2 trial sites

  • BioequivalenceWIM-2101A2021-12-28

    2 trial sites

  • BioequivalenceWIM-2101D2021-12-28

    2 trial sites

  • BioequivalenceWIM-2101D2021-12-28

    2 trial sites

  • BioequivalenceWIM-2101A2021-12-28

    2 trial sites

  • BioequivalenceWIE-1904TS2021-12-28

    2 trial sites

  • BioequivalenceWIG-21052021-12-10

    2 trial sites

  • BioequivalenceWIG-21072021-12-06

    2 trial sites

  • BioequivalenceWIG-20022021-12-01

    2 trial sites

  • Phase 3WID-RGC202021-04-16

    26 trial sites

  • Bioequivalence데팍신서방정2021-04-08

    2 trial sites

  • Bioequivalence데팍신서방정2021-04-07

    2 trial sites

  • BioequivalenceWIG-19032021-03-23

    2 trial sites

  • BioequivalenceWIG-19032021-03-23

    2 trial sites

  • BioequivalenceWIG-QX152021-02-26

    2 trial sites

  • BioequivalenceWIG-QX152021-02-26

    2 trial sites

  • BioequivalenceWIM-2301B2021-02-16

    2 trial sites

  • BioequivalenceWIM-2301B2021-02-16

    2 trial sites

  • Bioequivalence페라넬정6밀리그램2020-05-08

    2 trial sites

  • BioequivalenceWIG-QX152020-03-02

    2 trial sites

  • BioequivalenceWIG-QX152020-03-02

    2 trial sites

  • BioequivalenceWIM-2301B2020-02-07

    2 trial sites

  • BioequivalenceWIM-2301B2020-02-06

    2 trial sites

  • Bioequivalence라미펙솔서방정0.375밀리그램(프라미펙솔염산염일수화물)2019-09-19

    2 trial sites

  • Bioequivalence라미펙솔서방정0.375밀리그램(프라미펙솔염산염일수화물)2019-09-18

    2 trial sites

  • Bioequivalence라미펙솔정0.25밀리그램(프라미펙솔염산염일수화물)2019-09-18

    2 trial sites

  • BioequivalenceWIG-QX152019-07-05

    2 trial sites

  • BioequivalenceWIG-QX152019-07-05

    2 trial sites

  • Phase 1WID-ESL182019-07-03

    2 trial sites

  • Bioequivalence클로자릴정100밀리그램(클로자핀)2019-06-03

    14 trial sites

  • Bioequivalence팔페리돈서방캡슐6밀리그램(팔리페리돈)2019-05-21

    2 trial sites

  • Bioequivalence팔페리돈서방캡슐6밀리그램(팔리페리돈)2019-05-20

    2 trial sites

  • Phase 3WIP-RVX142019-03-11

    1 trial site

  • Phase 1WIP-DF172019-02-25

    2 trial sites

  • Phase 1WIP-DF172019-01-30

    2 trial sites

  • Bioequivalence미르젠탁오디정15밀리그램(미르타자핀)2018-10-30

    2 trial sites

  • Bioequivalence라사핀정(라사길린메실산염)2018-10-22

    1 trial site

  • Bioequivalence로나큐정8밀리그램(블로난세린)2018-03-14

    2 trial sites

  • Bioequivalence멜서타서방캡슐27밀리그램(메틸페니데이트염산염)2018-02-22

    2 trial sites

  • Bioequivalence케프렙톨서방정500밀리그램(레비티라세탐)2017-11-21

    2 trial sites

  • Bioequivalence케프렙톨서방정750밀리그램(레비티라세탐)2017-11-21

    2 trial sites

  • Bioequivalence환인두타스테리드정 0.5 밀리그램(가칭)2017-09-22

    2 trial sites

  • BioequivalenceWIG-QX152017-06-13

    2 trial sites

  • Bioequivalence환인쿠에티아핀서방정200밀리그램(가칭)2017-06-13

    2 trial sites

  • Bioequivalence환인미르타자핀오디정15 밀리그램(미르타자핀)(가칭)2017-02-03

    2 trial sites

  • Bioequivalence환인미르타자핀정15밀리그램(미르타자핀)(가칭)2017-02-03

    2 trial sites

  • Bioequivalence환인메만틴오디정10밀리그램2016-07-18

    2 trial sites

  • Bioequivalence쿠에타핀정12.5밀리그램(쿠에티아핀푸마르산염)2016-06-16

    2 trial sites

  • Bioequivalence네오마찐정100밀리그램(클로르프로마진염산염)2015-12-29

    2 trial sites

Showing the 80 most recent of 107 records.

Global clinical trials

ClinicalTrials.gov · sponsor-matched

R&D and key agreements

Source: DART corporate disclosure

WIL-1901 · 알츠하이머병 · GMP 생산 · Improved new drug; indication market size KRW 316.9bn

WIP-2401 · 우울증 · 생동 · Improved new drug; indication market size KRW 250bn

WIE-2301 · 본태성고혈압 · 생동 · Generic; indication market size KRW 1.2tn

WIE-2302 · 본태성고혈압 · 제제연구 · Generic; indication market size KRW 1.2tn

WIE-2303 · 위궤양 · Pilot PK · Generic; indication market size KRW 1,266.6bn

WIG-2202 · 뇌전증 · 허가 완료 · Generic; indication market size KRW 340bn

Publications

PubMed · affiliation-matched

Patents

KIPRIS · applicant-matched
Show 41 more patents

AI reads

MAA server logs · IP-verified
51
Times AI engines pulled WHANIN PHARM CO.,LTD's records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

1
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

50
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

8
live 0
Last 7 days
36
live 1
Last 30 days
51
live 1
All time
  • OpenAIChatGPT-Userlive1
  • OpenAIOAI-SearchBot41
  • PerplexityPerplexityBot4
  • GoogleGoogleOther2
  • AnthropicClaudeBot2
  • MicrosoftBingbot1

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 8, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for WHANIN PHARM CO.,LTD and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies in the same categoryPharma & CDMO

ILDONG HOLDINGS CO.,LTD100

Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.

Yuyu Pharma, Inc.100

Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.

IL DONG PHARMACEUTICAL CO., LTD.100

Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.

Medy-Tox Inc.99

Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.

GC Biopharma Corp.97

KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.

DAEWON PHARMACEUTICAL CO.,LTD85

KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.

SAMSUNG BIOLOGICS CO.,LTD.85

Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.

GENOLUTION INC.85

Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.

AHN-GOOK PHARMACEUTICAL Co., Ltd.85

Ahn-Gook Pharmaceutical sells the cough/expectorant drug Sinecuran and the eye-health supplement Tobicom.

CORESTEMCHEMON Inc.85

Founded in 2003 and listed on KOSDAQ in 2015, Corestem Chemon develops stem cell therapies and provides nonclinical CRO services, including the ALS treatment Neuronata-R.

BIO-FD&C CO.,LTD.85

Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.

HANDOK Inc.85

KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition